L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study aimed to investigate the efficacy and safety of L-DEP (L-Asparaginasum, liposomal
doxorubicin, etoposide and methylprednisolone) together with PD-1 antibody as an treatment
for relapse/refractory EBV associated hemophagocytic lymphohistiocytosis.